CELC vs MIAX Comparison

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Miami International Holdings Inc is engaged in operating regulated financial marketplaces across multiple asset classes using proprietary technology platforms. The company operates exchange markets for options, equities, futures, and international listings through its MIAX Exchanges, MIAX Futures Exchange, and the Bermuda Stock Exchange. The company operates through four reportable segments: Options, which provides trading and market data services for listed equity and ETP options; Equities, which provides trading services for U.S. equities and ETPs; Futures, which provides futures trading and clearing services through MIAX Futures; and International, which provides listing services for capital market instruments through the Bermuda Stock Exchange and The International Stock Exchange.